Learn more about Multiple Myeloma

Kyprolis in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

*Significant improvement in median progression-free survival with KRd combination treatment1

Now approved for use in the EU


  • 21ST EHA Annual Meeting & Exposition

    June 9–12 2016 Copenhagen, Denmark

    Click here for more

Multiple myeloma remains a challenging disease

Remission duration decreases with each line of therapy

MGUS, monoclonal gammopathy of unknown significance.

Despite substantial progress, the majority of patients with MM still fail to achieve optimal responses regardless of treatment regimen. MM currently remains incurable and most patients will relapse despite achievement of CR.2 In addition, as the disease progresses, clinical benefit decreases with each subsequent line of therapy.3

These diminishing responses experienced with successive treatment regimens likely reflect acquired drug resistance to prior therapy and individual disease biology.4 Hence, there continues to be an urgent unmet need for novel therapeutic approaches that provide high-quality responses and symptomatic relief, and maintain a good QoL for patients with relapsed or refractory MM5

Mode of action

  • Irreversible binding to the proteasome limits recovery from proteasome inhibition6
  • Potent and highly selective for inhibiting the chymotrypsin-like activity of the proteasome7
  • Powerful, sustained proteasome inhibition with the clinical dosing schedule7
KYPROLIS binds to β5 chymotrypsin-like (CT-L) protease (8)

A complete response in almost 1 out of 3 patients

Secondary endpoint analysis

Adapted from Stewart et al.1 * Descriptive P value

  • The Kyprolis-based regimen (KRd) showed deeper responses versus Rd1
Secondary endpoint analysis

Adapted from Stewart et al.1 * Descriptive P value

  • Almost 9 out of 10 patients achieved an overall response with the Kyprolis-based regimen1

Almost 9 out of 10 patients (87%) responded to treatment with the Kyprolis-based regimen1

ASPIRE – PFS by response category in the group of patients receiving the Kyprolis-based regimen (KRd)1

Adapted from Stewart et al.1 * Descriptive P value

Aim for deep responses in your patients with relapsed multiple myeloma1

Powerful efficacy for your patients with relapsed multiple myeloma

Primary endpoint analysis

Adapted from Stewart et al.1
*Kyprolis dose reduced from cycle 13 onwards.

With the Kyprolis-based regimen, aim for high efficacy for your relapsed multiple myeloma patients (median PFS)

A treatment with a tolerable safety profile

Adapted from Stewart et al.1­ Frequency of AEs may vary between studies. Refer to SmPC11 for selected AEs reported in clinical studies.

Click here for the summary of product characteristics

* Kyprolis was given at reduced frequency from cycles 13 to 18 (the day 8 and 9 doses of Kyprolis were omitted) and discontinued after 18 cycles1

The power* of 27mg/m2 Kyprolis in combination with Rd

* Significant improvement in median progression-free survival with KRd combination treatment1

** Kyprolis is given at reduced frequency from cycle 13 onward (the day 8 and 9 doses of Kyprolis are omitted). Treatment with the KRd regimen for longer than 18 cycles should be based on an individual benefit–risk assessment (limited data on the tolerability/toxicity of Kyprolis beyond 18 cycles). Refer to SmPC for full details of dose modifications.11

In the pivotal phase 3 ASPIRE trial, patients received treatment with the Kyprolis-based regimen (KRd) for up to 18 cycles1

Preparation for administration11

  1. Remove vial from refrigerator just before use.
  2. Aseptically reconstitute each vial by slowly injecting 29 mL sterile water for injections through the stopper and directing the solution onto the INSIDE WALL OF THE VIAL to minimise foaming. (figure 1)
  3. Gently swirl and/or invert the vial slowly for approximately 1 minute or until complete dissolution. DO NOT SHAKE. If foaming occurs, allow the solution to settle in the vial until foaming subsides (approximately 5 minutes) and the solution is clear.
  4. Visually inspect for particulate matter and discolouration prior to administration. The reconstituted product should be a clear, colourless to slightly yellow solution and should not be administered if any discolouration or particulate matter is observed.
  5. Discard any unused portion left in the vial.
  6. Optionally, Kyprolis can be administered in an intravenous bag: withdraw the calculated dose from the vial and dilute into a 50 mL intravenous bag containing 5% glucose solution for injection.
figure 1

Calculating dose based on actual baseline body surface area (BSA)11

Prior to all doses11

Storage and stability of reconstituted Kyprolis11

Click here for the summary of product characteristics


European Multiple Myeloma Experts

How the approval of KRd changed the outlook for relapsed multiple myeloma patients (ASH 2015)


New materials will be available here soon


  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Martinez-Lopez J, et al. Blood 2014;123:3073–3079.
  3. Gay F, et al. Blood 2011;117:3025–3031.
  4. Kumar SK, et al. Mayo Clin Proc 2004;79:867–874.
  5. Dimopoulos MA, et al. Eur J Haematol 2011;86:1–15.
  6. Orlowski RZ, Kuhn DJ. Clin Cancer Res 2008;14:1649–1657.
  7. Demo SD et al. Cancer Res 2007;67:6383–6391.
  8. San Miguel JF et al. N Engl J Med 2008;359:906–917.
  9. Benboubker L et al. N Engl J Med 2014;371:906–917.
  10. Dimopoulos MA et al. J Clin Oncol 33, 2015 (suppl; abstr 8525). Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. 29 May–2 June 2015, Chigago IL; USA.
  11. KYPROLIS (carfilzomib) Summary of Product Characteristics; 2015.


adverse event
phase 3 trial of carfilzomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone
confidence interval
complete response
hazard ratio
carfilzomib, lenalidomide and dexamethasone
multiple myeloma
minimal response
overall response rate
progressive disease
progression-free survival
partial response
lenalidomide and dexamethasone
stem cell transplant
stable disease
very good partial response

Summary of product characteristics

Terms of Use

The information contained in this site is for European healthcare professionals only.